Expression of immune genes on chromosome 6p21.3-22.1 in schizophrenia

Brain, Behavior, and Immunity

Volumn 32, Issue , 2013, Pages 51-62

  Sinkus, Melissa L ^a   Adams, Catherine E ^b   Logel, Judith ^a   Freedman, Robert ^a   Leonard, Sherry ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Brain; Gene expression; HLA A; HLA B; Immune genes; Inflammation; Postmortem; Schizophrenia; Smoking

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; BETA 2 MICROGLOBULIN; BUTYROPHILIN 2A2; HLA A ANTIGEN; HLA B ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MESSENGER RNA; NOTCH4 RECEPTOR; PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; AUTOPSY; BRAIN TISSUE; CHROMOSOME 6P; CONTROLLED STUDY; DENTATE GYRUS; DENTATE HILUS; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; HIPPOCAMPAL CA1 REGION; HIPPOCAMPAL CA2 REGION; HIPPOCAMPAL CA3 REGION; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; SCHIZOPHRENIA; SMOKING; STRATUM PYRAMIDALE;

EID: 84891371425     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2013.01.087     Document Type: Article

References (56)

1. Albensi, B.C., Mattson, M.P., 2000. Evidence for the involvement of TNF and NF-κB in hippocampal synaptic plasticity. Synapse 35, 151-159.
2. Andersen, C.L., Jensen, J.L., Ørntoft, T.F., 2004. Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res. 64, 5245-5250.
3. Benjamini, Y., Hochberg, Y., 1995. Controlling the false discovery rate-a practical and powerful approach to multiple testing. J. Royal Statistical Soc. Ser. BMethod. 57, 289-300.
4. Blank, T., Prinz, M., 2012. Microglia as modulators of cognition and neuropsychiatric disorders. Glia (ePub ahead of print).
5. Boulanger, L.M., 2009. Immune proteins in brain development and synaptic plasticity. Neuron 64, 93-109.
6. Brennand, K.J., Simone, A., Jou, J., Gelboin-Burkhart, C., Tran, N., Sangar, S., Li, Y., Mu, Y., Chen, G., Yu, D., McCarthy, S., Sebat, J., Gage, F.H., 2011. Modelling schizophrenia using human induced pluripotent stem cells. Nature 473, 221-225.
7. Brown, A.S., Derkits, E.J., 2009. Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. Am. J. Psychiatry 167, 261-280.
8. Brown, A.S., Hooton, J., Schaefer, C.A., Zhang, H., Petkova, E., Babulas, V., Perrin, M., Gorman, J.M., Susser, E.S., 2004. Elevated maternal interleukin-8 levels and risk of schizophrenia in adult offspring. Am. J. Psychiatry 161, 889-895.
9. Cazzullo, C.L., Sacchetti, E., Galluzzo, A., Panariello, A., Adorni, A., Pegoraro, M., Bosis, S., Colombo, F., Trabattoni, D., Zagliani, A., Clerici, M., 2002. Cytokine profiles in schizophrenic patients treated with risperidone: a 3-month follow-up study. Prog. Neuropsychopharmacol. Biol. Psychiatry 26, 33-39.
10. Chen, M.L., Tsai, T.C., Wang, L.K., Lin, Y.Y., Tsai, Y.M., Lee, M.C., Tsai, F.M., 2012. Risperidone modulates the cytokine and chemokine release of dendritic cells and induces TNF-directed cell apoptosis in neutrophils. Int. Immunopharmacol. 12, 197-204.
11. Corriveau, R.A., Huh, G.S., Shatz, C.J., 1998. Regulation of class I MHC gene expression in the developing and mature CNS by neural activity. Neuron 21, 505-520.
12. de Leon, J., Diaz, F.J., 2005. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophrenia Res. 76, 135-157.
13. Fellerhoff, B., Laumbacher, B., Mueller, N., Gu, S., Wank, R., 2006. Associations between Chlamydophila infections, schizophrenia and risk of HLA-A10. Mol. Psychiatry 12, 264-272.
14. Fellerhoff, B., Wank, R., 2009. Transporter associated with antigen processing and the chaperone tapasin: are non-classical HLA genes keys to the pathogenesis of schizophrenia? Med. Hypotheses 72, 535-538.
15. Fleige, S., Pfaffl, M.W., 2006. RNA integrity and the effect on the real-time qRT-PCR performance. Mol. Aspects Med. 27, 126-139.
16. Fleige, S., Walf, V., Huch, S., Prgomet, C., Sehm, J., Pfaffl, M., 2006. Comparison of relative mRNA quantification models and the impact of RNA integrity in quantitative real-time RT-PCR. Biotechnol. Lett. 28, 1601-1613.
17. Freedman, R., Olincy, A., Buchanan, R., Harris, J., Gold, J., Johnson, L., Allensworth, D., Guzman-Bonilla, A., Clement, B., Ball, M., Kutnick, J., Pender, V., Martin, L., Stevens, K., Wagner, B., Zerbe, G., Soti, F., Kem, W., 2008. Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am. J. Psychiatry 165, 1040-1047.
18. Freedman, R., Adler, L.E., MylesWorsley, M., Nagamoto, H.T., Miller, C., Kisley, M., McRae, K., Cawthra, E., Waldo, M., 1996. Inhibitory gating of an evoked response to repeated auditory stimuli in schizophrenic and normal subjects-human recordings, computer simulation, and an animal model. Arch. Gen. Psychiatry 53, 1114-1121.
19. Gallowitsch-Puerta, M., Tracey, K.J., 2005. Immunologic role of the cholinergic antiinflammatory pathway and the nicotinic acetylcholine alpha 7 receptor. Human Immunol.: Patient-Based Res. 1062, 209-219.
20. Gehrmann, J., Matsumoto, Y., Kreutzberg, G.W., 1995. Microglia: intrinsic immuneffector cell of the brain. Brain Res. Rev. 20, 269-287.
21. Gejman, P.V., Sanders, A.R., Kendler, K.S., 2011. Genetics of Schizophrenia: New Findings and Challenges. Annu. Rev. Genomics Hum. Genet. 12, 121-144.
22. Harrison, P.J., Heath, P.R., Eastwood, S.L., Burnet, P.W.J., McDonald, B., Pearson, R.C.A., 1995. The relative importance of premortem acidosis and postmortem interval for human brain gene expression studies: Selective mRNA vulnerability and comparison with their encoded proteins. Neurosci. Lett. 200, 151-154.
23. Heckers, S., Konradi, C., 2002. Hippocampal neurons in schizophrenia. J. Neural Transmission 109, 891-905.
24. Huh, G.S., Boulanger, L.M., Du, H.P., Riquelme, P.A., Brotz, T.M., Shatz, C.J., 2000. Functional requirement for class I MHC in CNS development and plasticity. Science 290, 2155-2159.
25. Kano, S.i., Nwulia, E., Niwa, M., Chen, Y., Sawa, A., Cascella, N., 2011. Altered MHC class I expression in dorsolateral prefrontal cortex of nonsmoker patients with schizophrenia. Neurosci. Res. 71, 289-293.
26. Khandaker, G.M., Zimbron, J., Dalman, C., Lewis, G., Jones, P.B., 2012. Childhood infection and adult schizophrenia: a meta-analysis of population-based studies. Schizophr. Res. 139, 161-168.
27. Kim, D.J., Kim, W.Y., Yoon, S.J., Go, H.J., Choi, B.M., Jun, T.Y., Kim, Y.K., 2001. Effect of risperidone on serum cytokines. Int. J. Neurosci. 111, 11.
28. Kolluri, N., Sun, Z.X., Sampson, A.R., Lewis, D.A., 2005. Lamina-specific reductions in dendritic spine density in the prefrontal cortex of subjects with schizophrenia. Am. J. Psychiatry 162, 1200-1202.
29. Krishnadas, R., Cavanagh, J., 2012. Depression: an inflammatory illness? J. Neurol. Neurosurg. Psychiatry 83, 495-502.
30. Law, A.J., Kleinman, J.E., Weinberger, D.R., Weickert, C.S., 2007. Disease-associated intronic variants in the ErbB4 gene are related to altered ErbB4 splice-variant expression in the brain in schizophrenia. Hum. Mol. Genet. 16, 129-141.
31. Leonard, S., Adler, L.E., Benhammou, K., Berger, R., Breese, C.R., Drebing, C., Gault, J., Lee, M.J., Logel, J., Olincy, A., Ross, R.G., Stevens, K., Sullivan, B., Vianzon, R., Vernich, D.E., Waldo, M., Walton, K., Freedman, R., 2001. Smoking and mental illness. Pharmacol. Biochem. Behav. 70, 561-570.
32. Meador-Woodruff, J.H., Healy, D.J., 2000. Glutamate receptor expression in schizophrenic brain. Brain Res. Rev. 31, 288-294.
33. Mexal, S., Berger, R., Adams, C.E., Ross, R.G., Freedman, R., Leonard, S., 2006. Brain pH has a significant impact on human postmortem hippocampal gene expression profiles. Brain Res. 1106, 1-11.
34. Mexal, S., Frank, M., Berger, R., Adams, C.E., Ross, R.G., Freedman, R., Leonard, S., 2005. Differential modulation of gene expression in the NMDA postsynaptic density of schizophrenic and control smokers. Mol. Brain Res. 139, 317-332.
35. Miller, A.H., Maletic, V., Raison, C.L., 2009. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol. Psychiatry 65, 732-741.
36. Neumann, H., Schmidt, H., Cavalie, A., Jenne, D., Wekerle, H., 1997. Major histocompatibility complex (MHC) class I gene expression in single neurons of the central nervous system: differential regulation by interferon (IFN)-gamma and tumor necrosis factor (TNF)-alpha. J. Exp. Med. 185, 305-316.
37. Newton, S.S., Dow, A., Terwilliger, R., Duman, R., 2002. A simplified method for combined immunohistochemistry and in-situ hybridization in fresh-frozen, cryocut mouse brain sections. Brain Res. protocols 9, 214-219.
38. Olincy, A., Young, D.A., Freedman, R., 1997. Increased levels of the nicotine metabolite cotinine in schizophrenic smokers compared to other smokers. Biol. Psychiatry 42, 1-5.
39. Pantelis, C., Yucel, M., Wood, S.J., Velakoulis, D., Sun, D., Berger, G., Stuart, G.W., Yung, A., Phillips, L., McGorry, P.D., 2005. Structural brain imaging evidence for multiple pathological processes at different stages of brain development in schizophrenia. Schizophr. Bull. 31, 672-696.
40. Patterson, P.H., 2007. Neuroscience. Maternal effects on schizophrenia risk. Science 318, 576-577.
41. Purcell, S.M., Wray, N.R., Stone, J.L., Visscher, P.M., O'Donovan, M.C., Sullivan, P.F., Sklar, P., 2009. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 460, 748-752.
42. Radewicz, K., Garey, L.J., Gentleman, S.M., Reynolds, R., 2000. Increase in HLA-DR immunoreactive microglia in frontal and temporal cortex of chronic schizophrenics. J. Neuropathol. Exp. Neurol. 59, 137-150.
43. Rosoklija, G., Derkits, E., Serafimova, T., Dika, A., Mancevski, B., Stankov, A., Davceva, N., Jakovski, Z., Pavlovski, G., Todorova, L., Todorov, B., Duma, A., Dwork, A.J., 2007. Post mortem studies of dendritic abnormalities in schizophrenia and mood disorders. Schizophr. Bull. 33, 271-272.
44. Schmeisser, M.J., Baumann, B., Johannsen, S., Vindedal, G.F., Jensen, V., Hvalby, Ø.C., Sprengel, R., Seither, J., Maqbool, A., Magnutzki, A., Lattke, M., Oswald, F., Boeckers, T.M., Wirth, T., 2012. IκB kinase/nuclear factor κB-dependent insulinlike growth factor 2 (Igf2) expression regulates synapse formation and spine maturation via Igf2 receptor signaling. J. Neurosci. 32, 5688-5703.
45. Schnell, S.A., Staines, W.A., Wessendorf, M.W., 1999. Reduction of lipofuscin-like autofluorescence in fluorescently labeled tissue. J. Histochem. Cytochem. 47, 719-730.
46. Shatz, C.J., 2002. Neural activity, immune genes and synaptic remodeling in brain development. FASEB J. 16, A378-A379.
47. Shatz, C.J., 2009. MHC class I: an unexpected role in neuronal plasticity. Neuron 64, 40-45.
48. Shenton, M.E., Dickey, C.C., Frumin, M., McCarley, R.W., 2001. A review of MRI findings in schizophrenia. Schizophr. Res. 49, 1-52.
49. Shi, J., Levinson, D.F., Duan, J., Sanders, A.R., Zheng, Y., Pe'er, I., Dudbridge, F., Holmans, P.A., Whittemore, A.S., Mowry, B.J., Olincy, A., Amin, F., Cloninger, C.R., Silverman, J.M., Buccola, N.G., Byerley, W.F., Black, D.W., Crowe, R.R., Oksenberg, J.R., Mirel, D.B., Kendler, K.S., Freedman, R., Gejman, P.V., 2009. Common variants on chromosome 6p22.1 are associated with schizophrenia. Nature 460, 753-757.
50. Smith, I.A., Knezevic, B.R., Ammann, J.U., Rhodes, D.A., Aw, D., Palmer, D.B., Mather, I.H., Trowsdale, J., 2010. BTN1A1, the mammary gland butyrophilin, and BTN2A2 are both inhibitors of T cell activation. J. Immunol. 184, 3514-3525.
51. Stefansson, H., Ophoff, R.A., Steinberg, S., Andreassen, O.A., Cichon, S., Rujescu, D., Werge, T., Pietilainen, O.P., Mors, O., Mortensen, P.B., Sigurdsson, E., Gustafsson, O., Nyegaard, M., Tuulio-Henriksson, A., Ingason, A., Hansen, T., Suvisaari, J., Lonnqvist, J., Paunio, T., Borglum, A.D., Hartmann, A., Fink-Jensen, A., Nordentoft, M., Hougaard, D., Norgaard-Pedersen, B., Bottcher, Y., Olesen, J., Breuer, R., Moller, H.J., Giegling, I., Rasmussen, H.B., Timm, S., Mattheisen, M., Bitter, I., Rethelyi, J.M., Magnusdottir, B.B., Sigmundsson, T., Olason, P., Masson, G., Gulcher, J.R., Haraldsson, M., Fossdal, R., Thorgeirsson, T.E., Thorsteinsdottir, U., Ruggeri, M., Tosato, S., Franke, B., Strengman, E., Kiemeney, L.A., Melle, I., Djurovic, S., Abramova, L., Kaleda, V., Sanjuan, J., de, F.R., Bramon, E., Vassos, E., Fraser, G., Ettinger, U., Picchioni, M., Walker, N., Toulopoulou, T., Need, A.C., Ge, D., Yoon, J.L., Shianna, K.V., Freimer, N.B., Cantor, R.M., Murray, R., Kong, A., Golimbet, V., Carracedo, A., Arango, C., Costas, J., Jonsson, E.G., Terenius, L., Agartz, I., Petursson, H., Nothen, M.M., Rietschel, M., Matthews, P.M., Muglia, P., Peltonen, L., St, C.D., Goldstein, D.B., Stefansson, K., Collier, D.A., 2009. Common variants conferring risk of schizophrenia. Nature 460, 744-747.
52. Stellwagen, D., Malenka, R.C., 2006. Synaptic scaling mediated by glial TNF-alpha. Nature 440, 1054-1059.
53. Stone, W.S., Hsi, X., 2011. Declarative memory deficits and schizophrenia: problems and prospects. Neurobiol. Learn. Mem. 96, 544-552.
54. Stone, W.S., Seidman, L.J., 2008. Toward a model of memory enhancement in schizophrenia: glucose administration and hippocampal function. Schizophr. Bull. 34, 93-108.
55. Wang, H., Yu, M., Ochani, M., Amella, C.A., Tanovic, M., Susarla, S., Li, J.H., Wang, H.C., Yang, H., Ulloa, L., Al-Abed, Y., Czura, C.J., Tracey, K.J., 2003. Nicotinic acetylcholine receptor alpha 7 subunit is an essential regulator of inflammation. Nature 421, 384-388.
56. Zhang, X.Y., Zhou, D.F., Cao, L.Y., Zhang, P.Y., Wu, G.Y., Shen, Y.C., 2004. Changes in serum interleukin-2,-6, and-8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia. J. clin. psychiatry 65, 940-947.